Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabella Bonilha

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The Journal of Dermatological Treatment|May 26, 2026
Effect of methotrexate on endothelial function in psoriasis patientsTiago Almeida Santos Costa, Isabella Bonilha, Sheila Tatsumi Kimura Medorima, et al.
The Journal of Clinical Endocrinology and Metabolism|June 14, 2021
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-yearsRiobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, et al.
Expert Opinion on Drug Safety|October 8, 2024
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional AnalysisJoaquim Barreto, Beatriz Luchiari, Vaneza L W Wolf, et al.
International Journal of Molecular Sciences|April 13, 2024
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 TrialIsabella Bonilha, Érica Ivana Lázaro Gomes, Helison R P Carmo, et al.
Research Square|October 27, 2023
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Therapeutic Advances in Chronic Disease|October 16, 2020
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trialIkaro Breder, Jessica Cunha Breder, Isabella Bonilha, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 14, 2019
Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial InfarctionAndrei C Sposito, José Carlos de Lima-Junior, Filipe A Moura, et al.
Cardiovascular Diabetology|March 27, 2026
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trialSheila T Kimura-Medorima, Daniela C Oliveira, Ikaro Breder, et al.
Cardiovascular Diabetology|March 27, 2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trialAndrei C Sposito, Ikaro Breder, Alexandre A S Soares, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Dermatological Treatment|May 26, 2026
Effect of methotrexate on endothelial function in psoriasis patientsTiago Almeida Santos Costa, Isabella Bonilha, Sheila Tatsumi Kimura Medorima, et al.
The Journal of Clinical Endocrinology and Metabolism|June 14, 2021
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-yearsRiobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, et al.
Expert Opinion on Drug Safety|October 8, 2024
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional AnalysisJoaquim Barreto, Beatriz Luchiari, Vaneza L W Wolf, et al.
International Journal of Molecular Sciences|April 13, 2024
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 TrialIsabella Bonilha, Érica Ivana Lázaro Gomes, Helison R P Carmo, et al.
Research Square|October 27, 2023
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Therapeutic Advances in Chronic Disease|October 16, 2020
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trialIkaro Breder, Jessica Cunha Breder, Isabella Bonilha, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 14, 2019
Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial InfarctionAndrei C Sposito, José Carlos de Lima-Junior, Filipe A Moura, et al.
Cardiovascular Diabetology|March 27, 2026
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trialSheila T Kimura-Medorima, Daniela C Oliveira, Ikaro Breder, et al.
Cardiovascular Diabetology|March 27, 2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trialAndrei C Sposito, Ikaro Breder, Alexandre A S Soares, et al.
Pageof 3